Dr. Seth P. Lerner
Claim this profileBaylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Studies Bladder Cancer
Studies Coronavirus Infection
5 reported clinical trials
9 drugs studied
Area of expertise
1Bladder Cancer
Stage II
Stage I
2Coronavirus Infection
Affiliated Hospitals
Clinical Trials Seth P. Lerner is currently running
CG0070
for Bladder Cancer
This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer. Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment Cohort C and Cohort P will be analyzed and reported separately. Patients will have had to fail prior BCG therapy which is defined as having persistent or recurrent disease within 12 months (Cohort C) or 6 months (Cohort P) following the completion of adequate BCG therapy for HGUC
Recruiting2 awards Phase 35 criteria
Pembrolizumab + Gemcitabine
for Bladder Cancer
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine may delay the return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone.
Recruiting1 award Phase 223 criteria
More about Seth P. Lerner
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Seth P. Lerner has experience with
- STM-416
- BCG Vaccine
- Placebo Vaccine
- CG0070
- Gemcitabine Hydrochloride
- Pembrolizumab
Breakdown of trials Seth P. Lerner has run
Bladder Cancer
Coronavirus Infection
Transitional Cell Carcinoma
Vulval Intraepithelial Neoplasia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Seth P. Lerner specialize in?
Seth P. Lerner focuses on Bladder Cancer and Coronavirus Infection. In particular, much of their work with Bladder Cancer has involved Stage II patients, or patients who are Stage I.
Is Seth P. Lerner currently recruiting for clinical trials?
Yes, Seth P. Lerner is currently recruiting for 4 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Seth P. Lerner has studied deeply?
Yes, Seth P. Lerner has studied treatments such as STM-416, BCG Vaccine, Placebo Vaccine.
What is the best way to schedule an appointment with Seth P. Lerner?
Apply for one of the trials that Seth P. Lerner is conducting.
What is the office address of Seth P. Lerner?
The office of Seth P. Lerner is located at: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.